SCHEMBL18923917

SCHEMBL18923917

O=S(=O)(Nc1cccc(-c2ccc(C3CC3)cc2)c1)N1CCNCC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 7/20 0.64
MAOA P21397 2/20 0.64
MAOB P27338 2/20 0.64
USP2 O75604 2/20 0.42
CYP1A2 P05177 2/20 0.42
CLK4 Q9HAZ1 2/20 0.42
LMNA P02545 2/20 0.42
CYP3A4 P08684 1/20 0.42
MAPK1 P28482 1/20 0.42
FKBP1A P62942 1/20 0.39
MMP3 P08254 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.39
USP30 Q70CQ3 1/20 0.39
P2RY14 Q15391 1/20 0.39
JAK2 O60674 1/20 0.39
BRD4 O60885 1/20 0.39
JAK1 P23458 1/20 0.39
BRD2 P25440 1/20 0.39
JAK3 P52333 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18923918 0.85 KDM1A (0.72) KDM1AMAOAMAOB
SCHEMBL16009812 0.79 KDM1A (1.00) KDM1AMAOAMAOB
SCHEMBL29357786 0.79 KDM1A (1.00) KDM1AMAOAMAOB
SCHEMBL29357936 0.79 KDM1A (1.00) KDM1AMAOAMAOB
SCHEMBL16010546 0.79 KDM1A (1.00) KDM1AMAOAMAOB
SCHEMBL16009813 0.79 KDM1A (1.00) KDM1AMAOAMAOB
SCHEMBL16009931 0.79 KDM1A (1.00) KDM1AMAOAMAOB
SCHEMBL16010056 0.79 KDM1A (1.00) KDM1AMAOAMAOB
SCHEMBL14882283 0.79 KDM1A (1.00) KDM1AMAOAMAOB
SCHEMBL14882286 0.79 KDM1A (1.00) KDM1AMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3495349-B1 (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS ORYZON GENOMICS SA (ES) 2023-06-28 EP disclosed
US-20180079709-A1 (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS ORYZON GENOMICS SA (ES) 2018-03-22 US disclosed
US-9670136-B2 (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors ORYZON GENOMICS S.A. (ES) 2017-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180079709-A1 (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS KDM1B, KDM1A, KDM2A KDM1A 2/4885MAOA 135/4885MAOB 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.